AKYA:NSD-Akoya Biosciences Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 13.10

Change

-0.10 (-0.76)%

Market Cap

USD 0.49B

Volume

0.21M

Avg Analyst Target

USD 17.40 (+32.82%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AKYA Stock Forecast & Price:
Based on the Akoya Biosciences Inc stock forecasts from 3 analysts, the average analyst target price for Akoya Biosciences Inc is USD 17.40 over the next 12 months. Akoya Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Akoya Biosciences Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Akoya Biosciences Inc’s stock price was USD 13.10. Akoya Biosciences Inc’s stock price has changed by +4.22% over the past week, +16.65% over the past month and -29.04% over the last year.

About Akoya Biosciences Inc (AKYA:NSD)

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact be ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical Inc

+0.65 (+0.32%)

USD73.98B 44.71 33.10
HOLX Hologic Inc

+0.05 (+0.07%)

USD17.49B 11.40 7.54
RGEN Repligen Corporation

+1.16 (+0.70%)

USD9.23B 64.29 38.66
XRAY Dentsply Sirona Inc

-0.10 (-0.28%)

USD7.80B 21.55 11.04
NVCR Novocure Ltd

+1.22 (+1.66%)

USD7.67B 1,480.87 -191.89
MASI Masimo Corporation

+0.75 (+0.55%)

USD7.54B 33.81 22.48
QDEL Quidel Corporation

+3.30 (+3.40%)

USD6.50B 4.11 3.91
AZTA Azenta Inc

+1.28 (+1.81%)

USD5.31B 2.39 174.55
ICUI ICU Medical Inc

-1.90 (-1.13%)

USD4.02B 80.48 30.94
STAA STAAR Surgical Company

+3.99 (+5.53%)

USD3.45B 120.32 78.81

ETFs Containing AKYA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.44% 82% B- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.44% 82% B- 59% F
Trailing 12 Months  
Capital Gain -29.80% 69% D+ 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.80% 69% D+ 46% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -8.76% 19% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.76% 19% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 19.11% 94% A 73% C
Risk Adjusted Return -45.84% 6% F 18% F
Market Capitalization 0.49B 48% F 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.66 21% F 18% F
Price / Cash Flow Ratio -13.65 79% C+ 80% B-
EV/EBITDA -10.40 84% B 86% B
Management Effectiveness  
Return on Equity -87.72% 12% F 14% F
Return on Invested Capital -37.85% 22% F 25% F
Return on Assets -22.75% 15% F 18% F
Debt to Equity Ratio 26.76% 60% D- 54% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 7.96 24% F 17% F
Short Percent 3.18% 61% D- 50% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector